|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
EP1065207A1
(de)
*
|
1999-07-02 |
2001-01-03 |
Aventis Pharma Deutschland GmbH |
Naphthyridin derivate, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende pharmazeutische Zusammenfassungen
|
|
EP1218360B1
(de)
|
1999-10-07 |
2008-05-28 |
Amgen Inc., |
Triazin-kinase-hemmer
|
|
DE19948417A1
(de)
*
|
1999-10-07 |
2001-04-19 |
Morphochem Ag |
Imidazol-Derivate und ihre Verwendung als Arzneimittel
|
|
AP1905A
(en)
|
1999-12-10 |
2008-10-20 |
Pfizer Prod Inc |
Pyrrolo[2,3-d] Pyrimidine Compounds.
|
|
WO2001052892A2
(en)
*
|
2000-01-24 |
2001-07-26 |
Genzyme Corporation |
Jak/stat pathway inhibitors and the uses thereof
|
|
EP1875900A3
(de)
*
|
2000-01-24 |
2010-07-21 |
Genzyme Corporation |
Inhibitoren des JAK/STAT-Weges und deren Verwendung zur Behandlung von Osteoathritis
|
|
MY145722A
(en)
*
|
2000-04-27 |
2012-03-30 |
Abbott Lab |
Diazabicyclic central nervous system active agents
|
|
ES2257410T3
(es)
*
|
2000-06-26 |
2006-08-01 |
Pfizer Products Inc. |
Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores.
|
|
US6881737B2
(en)
|
2001-04-11 |
2005-04-19 |
Amgen Inc. |
Substituted triazinyl acrylamide derivatives and methods of use
|
|
US6864255B2
(en)
|
2001-04-11 |
2005-03-08 |
Amgen Inc. |
Substituted triazinyl amide derivatives and methods of use
|
|
US7301023B2
(en)
*
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
|
HRP20031049A2
(en)
*
|
2001-06-23 |
2004-06-30 |
Aventis Pharma Inc |
Pyrrolopyrimidines as protein kinase inhibitors
|
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
|
US7323469B2
(en)
|
2001-08-07 |
2008-01-29 |
Novartis Ag |
7H-pyrrolo[2,3-d]pyrimidine derivatives
|
|
GT200200234A
(es)
|
2001-12-06 |
2003-06-27 |
|
Compuestos cristalinos novedosos
|
|
US6642381B2
(en)
*
|
2001-12-27 |
2003-11-04 |
Hoffman-La Roche Inc. |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
|
|
CN100503608C
(zh)
|
2002-01-07 |
2009-06-24 |
卫材R&D管理株式会社 |
脱氮嘌呤及其用途
|
|
GB0202679D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1388541A1
(de)
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazine als Kinasehemmer
|
|
CN1717236A
(zh)
|
2002-11-26 |
2006-01-04 |
辉瑞产品公司 |
治疗移植排斥的方法
|
|
WO2004093812A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Irm Llc |
Compounds that induce neuronal differentiation in embryonic stem cells
|
|
CA2543116A1
(en)
*
|
2003-10-27 |
2005-05-19 |
Genelabs Technologies, Inc. |
Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
|
|
WO2005069865A2
(en)
*
|
2004-01-13 |
2005-08-04 |
Ambit Biosciences Corporation |
Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
|
|
GB0403606D0
(en)
*
|
2004-02-18 |
2004-03-24 |
Novartis Ag |
Organic compounds
|
|
EP1750727A2
(de)
*
|
2004-04-23 |
2007-02-14 |
Exelixis, Inc. |
Kinasemodulatoren und verwendungsverfahren
|
|
EP1768662A2
(de)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Immunstimulatoren kleiner moleküle und assays für deren nachweis
|
|
CA2572314A1
(en)
|
2004-06-29 |
2006-01-12 |
Christopher N. Farthing |
Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
|
|
TW200615268A
(en)
|
2004-08-02 |
2006-05-16 |
Osi Pharm Inc |
Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
|
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
FR2880626B1
(fr)
*
|
2005-01-13 |
2008-04-18 |
Aventis Pharma Sa |
Derives de la purine, compositions les contenant et utilisation
|
|
WO2006091450A1
(en)
*
|
2005-02-18 |
2006-08-31 |
Lexicon Genetics Incorporated |
4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
|
|
EP1891066B1
(de)
|
2005-05-13 |
2010-12-22 |
Irm, Llc |
Verbindungen und zusammensetzungen als proteinkinase-hemmer
|
|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
|
WO2007007919A2
(en)
|
2005-07-14 |
2007-01-18 |
Astellas Pharma Inc. |
Heterocyclic janus kinase 3 inhibitors
|
|
EP2270014A1
(de)
|
2005-09-22 |
2011-01-05 |
Incyte Corporation |
Azepinhemmer von Janus-Kinasen
|
|
AU2006297351A1
(en)
|
2005-09-30 |
2007-04-12 |
Vertex Pharmaceuticals Incorporated |
Deazapurines useful as inhibitors of janus kinases
|
|
RS54181B9
(sr)
*
|
2005-12-13 |
2020-01-31 |
Incyte Holdings Corp |
Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
|
|
AU2015201850B2
(en)
*
|
2005-12-13 |
2017-03-02 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
BRPI0708779A2
(pt)
*
|
2006-03-11 |
2011-06-14 |
Vernalis R & D |
derivados de pirrolopirimidina utilizados como inibidores de hsp90
|
|
EP2001884A1
(de)
*
|
2006-04-05 |
2008-12-17 |
Vertex Pharmaceuticals, Inc. |
Deazapurine als janus-kinasehemmer
|
|
JP5606734B2
(ja)
*
|
2006-04-25 |
2014-10-15 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
|
GB0608176D0
(en)
*
|
2006-04-25 |
2006-06-07 |
Astex Therapeutics Ltd |
Pharmaceutical Compounds
|
|
WO2008012635A2
(en)
*
|
2006-07-26 |
2008-01-31 |
Pfizer Products Inc. |
Amine derivatives useful as anticancer agents
|
|
WO2008033747A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Curis, Inc. |
Multi-functional small molecules as anti-proliferative agents
|
|
US20080161320A1
(en)
*
|
2006-09-11 |
2008-07-03 |
Xiong Cai |
Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
|
|
AR064416A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Cancer Rec Tech Ltd |
Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
|
|
WO2008075007A1
(en)
*
|
2006-12-21 |
2008-06-26 |
Cancer Research Technology Limited |
Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
|
|
ES2415863T3
(es)
|
2006-12-22 |
2013-07-29 |
Incyte Corporation |
Heterociclos sustituidos como inhibidores de Janus Quinasas
|
|
TW200900061A
(en)
|
2007-01-12 |
2009-01-01 |
Astellas Pharma Inc |
Condensed pyridine compound
|
|
AR065901A1
(es)
*
|
2007-04-02 |
2009-07-08 |
Palau Pharma Sa |
Derivados de pirrolipirimidina
|
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
|
CN101932582B
(zh)
|
2007-06-13 |
2013-09-25 |
因塞特公司 |
詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
GB0713602D0
(en)
*
|
2007-07-12 |
2007-08-22 |
Syngenta Participations Ag |
Chemical compounds
|
|
ES2562218T3
(es)
*
|
2007-07-27 |
2016-03-03 |
Janssen Pharmaceutica, N.V. |
Pirrolopirimidinas útiles para el tratamiento de enfermedades proliferativas
|
|
CN101772502A
(zh)
|
2007-08-08 |
2010-07-07 |
莱西肯医药有限公司 |
作为激酶抑制剂用于治疗癌和炎症的(7H-吡咯并[2,3-d]嘧啶-4-基)哌嗪类化合物
|
|
WO2009030871A1
(en)
*
|
2007-09-07 |
2009-03-12 |
Vernalis R & D Ltd |
Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
|
|
ME01999B
(me)
|
2007-10-11 |
2015-05-20 |
Astrazeneca Ab |
Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b
|
|
BRPI0820544A2
(pt)
|
2007-11-16 |
2015-06-16 |
Incyte Corp |
4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
|
|
DK2288610T3
(en)
|
2008-03-11 |
2016-11-28 |
Incyte Holdings Corp |
Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS
|
|
EA019488B1
(ru)
|
2008-04-21 |
2014-04-30 |
Лексикон Фармасьютикалз, Инк. |
Ингибиторы limk2 и способы их применения
|
|
JP2011518836A
(ja)
|
2008-04-24 |
2011-06-30 |
インサイト・コーポレイション |
大環状化合物およびそれらのキナーゼ阻害剤としての使用
|
|
KR101335843B1
(ko)
|
2008-08-20 |
2013-12-02 |
조에티스 엘엘씨 |
피롤로[2,3-ｄ]피리미딘 화합물
|
|
US8385364B2
(en)
*
|
2008-09-24 |
2013-02-26 |
Nec Laboratories America, Inc. |
Distributed message-passing based resource allocation in wireless systems
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
JOP20190231A1
(ar)
|
2009-01-15 |
2017-06-16 |
Incyte Corp |
طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
|
|
DE102009005193A1
(de)
*
|
2009-01-20 |
2010-07-22 |
Merck Patent Gmbh |
Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
|
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
US8592415B2
(en)
|
2009-02-11 |
2013-11-26 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
|
BRPI1007737A2
(pt)
*
|
2009-04-20 |
2015-09-01 |
Auspex Pharmaceuticals Llc |
"composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii"
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
TWI484962B
(zh)
*
|
2009-05-22 |
2015-05-21 |
Incyte Corp |
作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈
|
|
CN102574857B
(zh)
*
|
2009-07-08 |
2015-06-10 |
利奥制药有限公司 |
作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
|
|
TWI466885B
(zh)
*
|
2009-07-31 |
2015-01-01 |
Japan Tobacco Inc |
含氮螺環化合物及其醫藥用途
|
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
EP2473049B1
(de)
|
2009-09-04 |
2018-11-28 |
Biogen MA Inc. |
Hemmer der bruton-tyrosinkinase
|
|
AU2010289321A1
(en)
|
2009-09-04 |
2012-04-05 |
The Regents Of The University Of Michigan |
Compositions and methods for treatment of leukemia
|
|
PL2486041T3
(pl)
|
2009-10-09 |
2014-01-31 |
Incyte Holdings Corp |
Pochodne hydroksylowe, keto i glukuronidowe 3-(4-(7H-pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo)-3-cyklopentylopropanonitrylu
|
|
JP5629324B2
(ja)
|
2009-10-15 |
2014-11-19 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジン化合物
|
|
US9074143B2
(en)
*
|
2009-12-11 |
2015-07-07 |
Uop Llc |
Process for producing hydrocarbon fuel
|
|
JP5739446B2
(ja)
|
2009-12-18 |
2015-06-24 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジン化合物
|
|
BR112012019511A2
(pt)
|
2010-02-05 |
2016-08-23 |
Pfizer |
compostos de pirrolo [2,3-d] pirimidina como inibidores de jak.
|
|
EA023444B1
(ru)
*
|
2010-02-18 |
2016-06-30 |
Инсайт Холдингс Корпорейшн |
Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения
|
|
KR101911697B1
(ko)
|
2010-03-10 |
2018-10-25 |
인사이트 홀딩스 코포레이션 |
Ｊａｋ１ 저해제로서의 피페리딘４일 아제티딘 유도체
|
|
KR102040479B1
(ko)
|
2010-05-21 |
2019-11-06 |
인사이트 홀딩스 코포레이션 |
Ｊａｋ 저해제에 대한 국소 제형
|
|
WO2012003829A1
(en)
*
|
2010-07-09 |
2012-01-12 |
Leo Pharma A/S |
Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
|
CN102372717B
(zh)
*
|
2010-08-20 |
2014-06-18 |
和记黄埔医药（上海）有限公司 |
吡咯并嘧啶类化合物及其用途
|
|
BR112013003864B1
(pt)
|
2010-08-20 |
2021-08-31 |
Hutchison Medipharma Limited |
Compostos de pirrolpirimidina, composição e uso dos mesmos
|
|
WO2012022045A1
(en)
*
|
2010-08-20 |
2012-02-23 |
Hutchison Medipharma Limited |
Pyrrolopyrimidine compounds and uses thereof
|
|
TWI401258B
(zh)
*
|
2010-09-08 |
2013-07-11 |
Hutchison Medipharma Ltd |
吡咯並嘧啶類化合物及其用途
|
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
|
NZ611151A
(en)
|
2010-11-19 |
2015-06-26 |
Incyte Corp |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
PL2651417T3
(pl)
|
2010-12-16 |
2017-08-31 |
Calchan Limited |
Pochodne pirolopirymidyny hamujące ASK1
|
|
WO2012088682A1
(en)
*
|
2010-12-29 |
2012-07-05 |
Shanghai Fochon Pharmaceutical Co Ltd. |
2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
|
CN103298817A
(zh)
*
|
2011-01-07 |
2013-09-11 |
利奥制药有限公司 |
作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
|
|
DE102011008352A1
(de)
*
|
2011-01-12 |
2012-07-12 |
Merck Patent Gmbh |
5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
|
|
JP5813785B2
(ja)
|
2011-02-04 |
2015-11-17 |
デュケイン ユニバーシティー オブ ザ ホリー スピリット |
抗チューブリン活性を有する二環式および三環式のピリミジンチロシンキナーゼ阻害剤ならびに患者の処置方法
|
|
EP2675451B9
(de)
|
2011-02-18 |
2017-07-26 |
Novartis Pharma AG |
Kombinationstherapie aus mtor/jak-hemmer
|
|
CN103547580B
(zh)
|
2011-03-22 |
2016-12-07 |
阿迪维纳斯疗法有限公司 |
取代的稠合三环化合物、其组合物及医药用途
|
|
AU2012235902B2
(en)
|
2011-04-01 |
2015-08-27 |
Astrazeneca Ab |
Therapeutic treatment
|
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
KR20140034862A
(ko)
*
|
2011-06-29 |
2014-03-20 |
머크 샤프 앤드 돔 코포레이션 |
키랄 디펩티딜 펩티다제-iv 억제제의 제조 방법
|
|
CN103732596B
(zh)
*
|
2011-07-08 |
2016-06-01 |
诺华股份有限公司 |
吡咯并嘧啶衍生物
|
|
JP2014521725A
(ja)
|
2011-08-10 |
2014-08-28 |
ノバルティス・ファルマ・アクチェンゲゼルシャフト |
ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
EP3750544B1
(de)
|
2011-11-30 |
2025-03-05 |
Emory University |
Jak-hemmer zur vorbeugung oder behandlung einer durch eine coronaviridae verursachte viralen krankheit
|
|
SG11201401471PA
(en)
|
2011-11-30 |
2014-08-28 |
Astrazeneca Ab |
Combination treatment of cancer
|
|
WO2013085802A1
(en)
*
|
2011-12-06 |
2013-06-13 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
CN105732639A
(zh)
*
|
2012-06-29 |
2016-07-06 |
辉瑞大药厂 |
作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
|
|
CN104981247A
(zh)
|
2012-09-06 |
2015-10-14 |
普莱希科公司 |
用于激酶调节的化合物和方法及其适应症
|
|
IN2015DN02008A
(de)
|
2012-09-21 |
2015-08-14 |
Advinus Therapeutics Ltd |
|
|
CA2881070A1
(en)
*
|
2012-10-26 |
2014-05-01 |
F. Hoffmann-La Roche Ag |
Inhibitors of bruton's tyrosine kinase
|
|
CN102936251A
(zh)
*
|
2012-11-05 |
2013-02-20 |
上海毕得医药科技有限公司 |
一种吡咯并[2,3-d]嘧啶衍生物的制备方法
|
|
BR112015010663B1
(pt)
|
2012-11-15 |
2022-12-06 |
Incyte Holdings Corporation |
Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
|
|
AU2014220357B2
(en)
|
2013-02-22 |
2017-04-27 |
Pfizer Inc. |
Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of Janus- related Kinases (JAK)
|
|
BR112015021458B1
(pt)
|
2013-03-06 |
2022-06-07 |
Incyte Holdings Corporation |
"processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
|
|
WO2014139388A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
AU2014305989B2
(en)
|
2013-08-07 |
2019-11-28 |
Incyte Holdings Corporation |
Sustained release dosage forms for a JAK1 inhibitor
|
|
DK3318565T3
(da)
|
2013-12-05 |
2021-05-25 |
Pfizer |
Pyrrolo[2,3-D]pyrimidinyl-, pyrrolo[2,3-B]pyrazinyl- og pyrrolo[2,3-D]pyridinylacrylamider
|
|
WO2015092592A1
(en)
|
2013-12-17 |
2015-06-25 |
Pfizer Inc. |
Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
ES2750655T3
(es)
|
2014-08-12 |
2020-03-26 |
Pfizer |
Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
|
|
US10246464B2
(en)
|
2014-09-09 |
2019-04-02 |
The Regents Of The University Of Michigan |
Thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
CN105524067A
(zh)
*
|
2014-09-28 |
2016-04-27 |
江苏柯菲平医药股份有限公司 |
4-取代吡咯并[2,3-d]嘧啶化合物及其用途
|
|
WO2016178110A1
(en)
|
2015-05-01 |
2016-11-10 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
|
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
|
|
US10588907B2
(en)
|
2015-06-04 |
2020-03-17 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
|
MA42544A
(fr)
|
2015-07-31 |
2018-06-06 |
Taiho Pharmaceutical Co Ltd |
COMPOSÉ PYRROLO[2,3-d]PYRIMIDINE OU UN SEL DE CELUI-CI
|
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
EP3350178B1
(de)
|
2015-09-14 |
2021-10-20 |
Pfizer Inc. |
Neuartige imidazo[4,5-c]chinolin- und imidazo[4,5-c][1,5]naphthyridin-derivate als lrrk2-inhibitoren
|
|
US10045981B2
(en)
|
2015-11-24 |
2018-08-14 |
Jakpharm, Llc |
Selective kinase inhibitors
|
|
CN107098908B
(zh)
*
|
2016-02-23 |
2021-01-08 |
欣凯医药科技(上海)有限公司 |
一种吡咯并嘧啶类化合物的制备方法和应用
|
|
US10781218B2
(en)
|
2016-03-16 |
2020-09-22 |
Kura Oncology, Inc. |
Substituted inhibitors of menin-MLL and methods of use
|
|
CA3015845A1
(en)
|
2016-03-16 |
2017-09-21 |
Kura Oncology, Inc. |
Bridged bicyclic inhibitors of menin-mll and methods of use
|
|
CN107513067A
(zh)
|
2016-06-16 |
2017-12-26 |
北京赛林泰医药技术有限公司 |
含有取代环戊基的吡咯并嘧啶化合物
|
|
CN107513069A
(zh)
*
|
2016-06-16 |
2017-12-26 |
正大天晴药业集团股份有限公司 |
手性吡咯并嘧啶化合物的制备方法
|
|
EP3487852A1
(de)
|
2016-07-21 |
2019-05-29 |
Biogen MA Inc. |
Succinatformen und zusammensetzungen von hemmern der bruton-tyrosinkinase
|
|
US10316038B2
(en)
|
2017-01-25 |
2019-06-11 |
Aclaris Therapeutics, Inc. |
Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
|
|
EP3576743B1
(de)
*
|
2017-02-03 |
2023-01-18 |
LEO Pharma A/S |
5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2 5]octane-8-carbonsäure-derivate als jak-kinase-hemmer
|
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
|
CN108794480A
(zh)
*
|
2017-04-28 |
2018-11-13 |
天津药物研究院有限公司 |
吡咯并嘧啶类化合物、其制备方法和用途
|
|
WO2018226976A1
(en)
|
2017-06-08 |
2018-12-13 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
EP3684361A4
(de)
|
2017-09-20 |
2021-09-08 |
Kura Oncology, Inc. |
Substituierte inhibitoren von menin-mll und verfahren zur verwendung
|
|
KR102821964B1
(ko)
|
2017-11-03 |
2025-06-19 |
어클라리스 쎄라퓨틱스, 인코포레이티드 |
치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
|
|
US10800775B2
(en)
|
2017-11-03 |
2020-10-13 |
Aclaris Therapeutics, Inc. |
Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
|
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
|
LT3746429T
(lt)
|
2018-01-30 |
2022-05-10 |
Incyte Corporation |
(1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai
|
|
CA3095487A1
(en)
|
2018-03-30 |
2019-10-03 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
|
BR112021002479A2
(pt)
|
2018-08-10 |
2021-07-27 |
Aclaris Therapeutics, Inc. |
composto, composição farmacêutica, método para inibir a atividade de itk ou jak3 em uma população de células, método para tratar um distúrbio mediado por itk ou jak3 em um indivíduo necessitando do mesmo e uso de um composto
|
|
GB201818750D0
(en)
*
|
2018-11-16 |
2019-01-02 |
Institute Of Cancer Res Royal Cancer Hospital |
Lox inhibitors
|
|
CN109394768B
(zh)
*
|
2018-12-10 |
2019-08-23 |
牡丹江医学院 |
一种治疗湿疹的药物及其制备方法
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
EP3946606B1
(de)
|
2019-03-27 |
2025-01-01 |
Insilico Medicine IP Limited |
Bicyclische jak-inhibitoren und verwendungen davon
|
|
WO2020223728A1
(en)
|
2019-05-02 |
2020-11-05 |
Aclaris Therapeutics, Inc. |
Substituted pyrrolopyridines as jak inhibitors
|
|
BR112021022682A2
(pt)
|
2019-05-14 |
2022-02-22 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes do tipo 1
|
|
BR112022009710A2
(pt)
|
2019-11-22 |
2022-08-09 |
Incyte Corp |
Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
BR112022025381A2
(pt)
|
2020-06-11 |
2023-01-24 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes tipo 1
|
|
US20250051337A1
(en)
*
|
2021-09-28 |
2025-02-13 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
|